title: [Assessment of novel antidiabetic drugs in Germany. Do innovations still have a chance?].
authors.forename: Baptist
authors.initials: B
authors.lastname: Gallwitz
mesh_terms: D000284:Administration, Oral; D000367:Age Factors; D032921:Consensus; D003365:Costs and Cost Analysis / Q000191:economics / Q000331:legislation & jurisprudence; D048909:Diabetes Complications / Q000191:economics / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D017277:Drug Approval; D016527:Drug Costs / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics; D015507:Drugs, Investigational / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D005858:Germany; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D009313:National Health Programs / Q000191:economics; D018027:Receptors, Glucagon / Q000037:antagonists & inhibitors
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D015507:Drugs, Investigational; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D018027:Receptors, Glucagon